一種新技術(shù)叫做光學(xué)彌散成像和分光光度計(jì)，允許開(kāi)展無(wú)創(chuàng)傷、直接、實(shí)時(shí)地測(cè)定局部氧飽和度，而且費(fèi)用低廉。新型組織血氧測(cè)定儀整合了這項(xiàng)技術(shù)，已經(jīng)獲得了美國(guó)食品藥物管理局地許可。

新型血氧測(cè)定儀叫做ODISsey，是由ViOptix公司研制開(kāi)發(fā)的，該公司是一家組織氧測(cè)定設(shè)備的開(kāi)發(fā)商和制造商。新技術(shù)將做為診斷與監(jiān)測(cè)設(shè)備，臨床用途極為廣泛。

ViOptix公司總裁兼首席執(zhí)行官M(fèi)ohamed Elmandjra指出：“對(duì)我們公司以及對(duì)無(wú)創(chuàng)性組織氧檢測(cè)而言，這是一項(xiàng)重要成就。我們致力于發(fā)展各種創(chuàng)新產(chǎn)品，對(duì)健康保健市場(chǎng)具有極高的臨床應(yīng)用價(jià)值。食品藥品管理局的許可對(duì)我們達(dá)到該目標(biāo)是一個(gè)重要的里程碑?！?/P>

Novel Tissue Oximeter Technology
 
New technology called optical diffusion imaging and spectroscopy (ODIS) enables noninvasive, direct, real-time estimation of local tissue oxygen saturation (StO2) on a very cost-effective basis. A new tissue oximeter incorporating the technology has been cleared by the U.S. Food and Drug Administration (FDA).

The new oximeter is called ODISsey and was developed by ViOptix (Fremont, CA, USA), a developer and manufacturer of tissue oxygen measuring devices. The new technology will be used in diagnostic and monitoring equipment for a wide variety of clinical applications.

“This is a key achievement for us and for noninvasive tissue oxygen assessment in general,” noted Mohamed Elmandjra, president and CEO of ViOptix. “We are committed to bringing innovative products with high clinical value to the healthcare market, and FDA clearance is definitely a major milestone toward that goal.”